How would you manage a patient with a high-risk asymptomatic bone metastasis with a driver mutation?  

For example, if the patient had an ALK+ NSCLC initiating targeted therapy, would you offer prophylactic radiotherapy as per Gillespie et al JCO 2024, or first rely on targeted therapy, and only treat if the patient becomes symptomatic or failed to respond?